What we are studying
The purpose of this study is to compare the effects, good or bad, of atezolizumab versus observation (not receiving any treatment) on you and your bladder cancer to find out which is better. In this study, you will get either atezolizumab or no treatment. Atezolizumab is an experimental drug, which means that health authorities have not approved atezolizumab for the treatment of bladder cancer.
Atezolizumab is an antibody (a protein produced by the body's immune system) that affects the immune system by blocking the programmed death-ligand 1 (PD-L1) pathway. The PD-L1 pathway is involved in regulating the body’s natural immune response, but tumors can take advantage of this regulation to partially resist or evade the immune system. By blocking the PD L1 pathway, atezolizumab may help your immune system to stop or reverse the growth of tumors. Your study doctor will give you atezolizumab in the hospital.